Monoclonal antibody therapy for prostate cancer: Finally a reality?

Journal of Clinical Oncology

Volumn 22, Issue 13, 2004, Pages 2515-2516

  Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CAPROMAB PENDETIDE IN 111; CELL SURFACE PROTEIN; CETUXIMAB; GEMTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J591; PROSTATE SPECIFIC ANTIGEN; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN;

ANTIGEN BINDING; BONE MARROW TUMOR; BREAST CANCER; CANCER GRADING; CLINICAL TRIAL; COLORECTAL CARCINOMA; DOSE RESPONSE; EDITORIAL; HUMAN; METASTASIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSTATE CANCER; IMMUNOLOGY; IMMUNOTHERAPY; MALE; NOTE; PROSTATE TUMOR;

ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; CLINICAL TRIALS; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS;

EID: 4344662130     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.04.901     Document Type: Editorial

References (3)

1. Milowsky MI, Nanus DM, Kostakoglu L, et al: Phase I trial of yttrium-90-labeled antiprostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 22:2522-2531, 2004
2. Kahn D, Williams RD, Manyak MJ, et al: 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol 159:2041-2046, 1998
3. Bander NH, Nanus D, Goldsmith S, et al: Phase I trial of humanized monoclonal antibody (mAb) to prostate specific membrane antigen/extracellular domain (PSMAext). Proc Am Soc Clin Oncol 19:477a, 2000 (abstr 1872)